China SXT Pharmaceuticals (SXTC) Competitors $1.83 -0.21 (-10.29%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.01 (+0.82%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SXTC vs. PLX, CABA, THTX, CCCC, ATOS, CRBU, EXOZ, CRDL, IVVD, and CTNMShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include Protalix BioTherapeutics (PLX), Cabaletta Bio (CABA), Theratechnologies (THTX), C4 Therapeutics (CCCC), Atossa Therapeutics (ATOS), Caribou Biosciences (CRBU), Exozymes (EXOZ), Cardiol Therapeutics (CRDL), Invivyd (IVVD), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. Its Competitors Protalix BioTherapeutics Cabaletta Bio Theratechnologies C4 Therapeutics Atossa Therapeutics Caribou Biosciences Exozymes Cardiol Therapeutics Invivyd Contineum Therapeutics Protalix BioTherapeutics (NYSE:PLX) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Does the media prefer PLX or SXTC? In the previous week, China SXT Pharmaceuticals had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for China SXT Pharmaceuticals and 0 mentions for Protalix BioTherapeutics. China SXT Pharmaceuticals' average media sentiment score of 0.43 beat Protalix BioTherapeutics' score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Protalix BioTherapeutics Neutral China SXT Pharmaceuticals Neutral Is PLX or SXTC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. China SXT Pharmaceuticals' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% China SXT Pharmaceuticals N/A N/A N/A Do analysts rate PLX or SXTC? Protalix BioTherapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 906.71%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Protalix BioTherapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer PLX or SXTC? China SXT Pharmaceuticals received 69 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 81.25% of users gave Protalix BioTherapeutics an outperform vote while only 61.65% of users gave China SXT Pharmaceuticals an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1381.25% Underperform Votes318.75%China SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Which has preferable valuation and earnings, PLX or SXTC? Protalix BioTherapeutics has higher revenue and earnings than China SXT Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$59.76M1.98$8.31M$0.0437.25China SXT Pharmaceuticals$1.82M15.93-$3.10MN/AN/A Which has more volatility & risk, PLX or SXTC? Protalix BioTherapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PLX or SXTC? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryProtalix BioTherapeutics and China SXT Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.97M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6419.64Price / Sales15.93262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book0.066.536.974.60Net Income-$3.10M$143.25M$3.23B$248.06M7 Day Performance-12.44%0.21%-0.98%-1.03%1 Month Performance-9.85%10.92%7.70%3.50%1 Year Performance-79.01%2.44%31.32%12.68% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals0.3811 of 5 stars$1.83-10.3%N/A-77.4%$28.97M$1.82M0.0090Positive NewsShort Interest ↑Gap DownPLXProtalix BioTherapeutics2.5961 of 5 stars$1.54-2.5%$15.00+874.0%+30.0%$122.60M$59.76M-11.85200CABACabaletta Bio2.8578 of 5 stars$2.37-4.4%$20.33+757.9%-85.2%$120.26MN/A-1.1050News CoverageAnalyst ForecastAnalyst RevisionGap DownTHTXTheratechnologiesN/A$2.60+0.8%N/A+99.2%$119.55M$88.67M-26.00140Positive NewsCCCCC4 Therapeutics2.1842 of 5 stars$1.68-2.9%$12.00+614.3%-67.3%$119.29M$39.78M-0.99150Positive NewsGap UpATOSAtossa Therapeutics1.4686 of 5 stars$0.91+1.6%$6.17+574.6%-32.6%$118.07MN/A-4.168CRBUCaribou Biosciences3.414 of 5 stars$1.27+0.8%$8.50+569.3%-41.1%$117.19M$9.92M-0.77100Positive NewsAnalyst RevisionGap DownEXOZExozymesN/A$13.96+3.9%N/AN/A$116.82MN/A0.0029CRDLCardiol Therapeutics2.2084 of 5 stars$1.44+2.1%$8.67+501.9%-51.5%$116.54MN/A-3.6920Gap UpIVVDInvivyd3.7693 of 5 stars$0.97-2.1%$5.85+504.2%-48.7%$116.15M$36.69M-0.49100Positive NewsGap DownCTNMContineum Therapeutics2.5472 of 5 stars$4.48-5.7%$22.50+402.2%-72.2%$115.91M$50M-2.2731 Related Companies and Tools Related Companies Protalix BioTherapeutics Alternatives Cabaletta Bio Alternatives Theratechnologies Alternatives C4 Therapeutics Alternatives Atossa Therapeutics Alternatives Caribou Biosciences Alternatives Exozymes Alternatives Cardiol Therapeutics Alternatives Invivyd Alternatives Contineum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTC) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SXTC Stock Free SXTC Stock Alerts